Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fordadistrogene-movaparvovec (Primary)
Indications Duchenne muscular dystrophy
Focus Registrational; Therapeutic Use
Acronyms CIFFREO
Sponsors Pfizer

Most Recent Events

13 Jan 2025 Planned End Date changed from 19 Apr 2029 to 15 Apr 2039.
15 Jun 2024 Planned End Date changed from 18 Apr 2029 to 19 Apr 2029.
12 Jun 2024 According to a Pfizer media release, company plans to share more detailed results from the study at upcoming medical meeting.Pfizer will continue to closely monitor all participants enrolled in the study and is evaluating appropriate next steps for the program.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com